Fig. 7: EMRMs have higher immune capacity than BMRMs.

EMRMs are more sensitive to immune challenges than BMRMs in vivo (a–e) and in vitro (f, g). a Representative histogram (upper panel) and MFI (lower panel) of CD86 expression on hCD59+ EMRMs and hCD59− BMRMs 2 h after PBS (Vehicle) or BSA-RαBSA injection. (n = 7 mice per group). b The percentage of TNF positive staining in EMRMs and BMRMs 2 h after PBS (Vehicle) or BSA-RαBSA injection. Left panel is representative dot plots. Right panel is the percentage of TNF+ cells (n = 4 mice for vehicle group; n = 6 mice for BSA-RαBSA group). c MFI of CD86 expression and d TNF staining in EMRMs and BMRMs 2 h and 24 h after αGBM serum injection in sheep IgG-preimmunized female mice. Data are pooled from two independent experiments (n = 4 mice per time point per group). e TNF staining in EMRMs and BMRMs 3 h after PBS or 5 µg/g b.w. LPS injection in male mice. Data are pooled from two independent experiments. (n = 4 mice for PBS group; n = 5 for LPS group). f TNF and g IL-6 level in the supernatant of sorted EMRMs and BMRMs treated with medium (NC), 100 ng/ml LPS, 5 µg/ml LTA, or 5 µg/ml Poly (I:C) for 18 h. Data are pooled from three independent experiments, each dot represents cells obtained from individual sorting pooled from two mice. (n = 5 for NC; n = 6 for LPS; n = 3 for LTA and Poly (I:C)). All data are presented as mean ± s.e.m. p-values by two-tailed unpaired t-test are indicated in a–g. Source data are provided as a Source Data file.